While targeting ERBB2 has proven effective, challenges remain. One major issue is the development of resistance to HER2-targeted therapies. Cancer cells can adapt to bypass the blocked pathways or activate alternative survival pathways. Additionally, the heterogeneity of tumors means that not all cancer cells may overexpress HER2, leading to incomplete treatment efficacy. Research continues to address these challenges by developing new combination therapies and drugs that target multiple pathways.
